Table 4.
Factors Associated with CDKN2A/B Co-deletion
| +CDKN2A/B co-del | −CDKN2A/B co-del | P-value | |
|---|---|---|---|
| Age | 64.8 ± 3.2 | 62.7 ± 1.7 | 0.58 |
| Male | 9 (42.9%) | 32 (45.7%) | 0.82 |
| Female | 12 (57.1%) | 38 (54.3%) | |
| Preop KPS | 74.3 ± 2.5 | 77.7 ± 1.4 | 0.24 |
| Minority | 6 (28.6%) | 19 (27.1%) | 0.90 |
| Non-minority | 15 (71.4%) | 51 (72.9%) | |
| Primary cancer | 0.13 | ||
| NSCLC | 9 (42.9%) | 13 (18.6%) | |
| Breast | 2 (9.5%) | 13 (18.6%) | |
| Melanoma | 6 (28.6%) | 16 (22.9%) | |
| GI | 3 (14.3%) | 9 (12.9%) | |
| Gyn | 0 (0%) | 4 (5.7%) | |
| RCC | 1 (4.8%) | 3 (4.3%) | |
| Other | 0 (0%) | 12 (17.1%) | |
| No. total brain mets at surgery | 2.95 ± 0.9 | 3.33 ± 0.5 | 0.71 |
| Tumor volume | 18.3 ± 4.6 | 22.5 ± 2.5 | 0.42 |
| Cystic | 4 (19.1%) | 14 (20%) | 0.92 |
| Non-cystic | 17 (80.9%) | 56 (80%) | |
| Hemorrhage | 11 (52.4%) | 36 (51.4%) | 0.94 |
| No hemorrhage | 10 (47.6%) | 34 (48.6%) | |
| Time from BM diagnosis to surgery | 6.0 ± 1.7 | 2.6 ± 0.9 | 0.08 |
| Presence of extracranial disease | 14 (66.7%) | 46 (65.7%) | 0.94 |
| Absence of extracranial disease | 7 (33.3%) | 24 (34.3%) | |
| Side | 0.59 | ||
| Left | 11 (52.4%) | 32 (45.7%) | |
| Right | 10 (47.6%) | 35 (50%) | |
| Midline | 0 (0%) | 3 (4.3%) | |
| Location | 0.64 | ||
| Frontal | 7 (33.3%) | 19 (27.1%) | |
| Parietal | 4 (19.1%) | 20 (28.6%) | |
| Temporal | 4 (19.1%) | 12 (17.1%) | |
| Occipital | 4 (19.1%) | 7 (10%) | |
| Cerebellum | 2 (9.5%) | 12 (17.1%) | |
| EOR | 0.60 | ||
| GTR | 17 (80.9%) | 60 (85.7%) | |
| STR | 4 (19.1%) | 10 (14.3%) | |
| Prior intracranial radiotherapy | 0.0083 | ||
| Yes | 8 (38.1%) | 8 (11.4%) | |
| No | 13 (61.9%) | 62 (88.6%) | |
| Postoperative radiotherapy type | 0.19 | ||
| Local RT | 16 (76.2%) | 58 (82.9%) | |
| WBRT | 2 (9.5%) | 1 (1.4%) | |
| None | 3 (14.3%) | 11 (15.7%) | |
| Length of follow-up | 11.5 ± 2.7 | 13.3 ± 1.5 | 0.55 |
Abbreviations: KPS, Karnofsky Performance Scale; NSCLC, non-small cell lung cancer; GI, gastrointestinal; Gyn, gynecologic; RCC, renal cell carcinoma; GTR, gross total resection; STR, subtotal resection; CNS, central nervous system; RT, radiation therapy; WBRT, whole brain radiation therapy.